First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: real-world experience from >2000 patients treated in the multicentre AVANTI study
Aim - The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing regimens for HER2-negative locally recurrent/metastatic breast cancer (LR/MBC) in German routine oncology practice. - Methods - Eligible...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2021
|
| In: |
The breast
Year: 2021, Jahrgang: 60, Pages: 70-77 |
| ISSN: | 1532-3080 |
| DOI: | 10.1016/j.breast.2021.08.014 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.breast.2021.08.014 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0960977621004446 
|
| Verfasserangaben: | Volkmar Müller, Markus Ruhnke, Oliver Hoffmann, Andrea Grafe, Oliver Tomé, Werner Fett, Harald-Robert Bruch, Ann-Katrin Sommer-Joos, Andreas Schneeweiss |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1824563922 | ||
| 003 | DE-627 | ||
| 005 | 20230426081044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221206s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2021.08.014 |2 doi | |
| 035 | |a (DE-627)1824563922 | ||
| 035 | |a (DE-599)KXP1824563922 | ||
| 035 | |a (OCoLC)1361713892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Müller, Volkmar |d 1967- |e VerfasserIn |0 (DE-588)12133497X |0 (DE-627)081238053 |0 (DE-576)292653719 |4 aut | |
| 245 | 1 | 0 | |a First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer |b real-world experience from >2000 patients treated in the multicentre AVANTI study |c Volkmar Müller, Markus Ruhnke, Oliver Hoffmann, Andrea Grafe, Oliver Tomé, Werner Fett, Harald-Robert Bruch, Ann-Katrin Sommer-Joos, Andreas Schneeweiss |
| 264 | 1 | |c December 2021 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffenticht am 27. August 2021, Artikelversion vom 3. September 2021 | ||
| 500 | |a Gesehen am 06.12.2022 | ||
| 520 | |a Aim - The multicentre non-interventional AVANTI study assessed safety, effectiveness and patient-reported outcomes with approved first-line bevacizumab-containing regimens for HER2-negative locally recurrent/metastatic breast cancer (LR/MBC) in German routine oncology practice. - Methods - Eligible patients had HER2-negative LR/MBC, no bevacizumab contraindications and no prior chemotherapy for LR/MBC. Chemotherapy schedule, diagnostics and follow-up were at physicians’ discretion. Data were collected for 1 year after starting bevacizumab, then every 6 months for 1.5 years (maximum follow-up: 2.5 years). Patients and physicians rated treatment satisfaction. Subgroup analyses were prespecified in clinically relevant populations, including triple-negative breast cancer (TNBC). - Results - Between November 1, 2009 and April 30, 2016, 2065 eligible patients at 346 centres received bevacizumab with paclitaxel or capecitabine. Patients receiving bevacizumab-capecitabine were less likely to have de novo disease and more likely to have TNBC, age ≥60 years and prior anthracycline/taxane and/or endocrine therapy. Median PFS was 12.6 (95% CI 11.9-13.2) months (12.8 with bevacizumab-paclitaxel, 10.5 with bevacizumab-capecitabine); median OS was 23.9 (95% CI 22.2-25.1) months. Outcomes were worse in patients with TNBC, prior anthracycline/taxane or prior endocrine therapy. Grade ≥3 adverse events occurred in 27% of patients. Treatment was discontinued for adverse events in 15%. Treatment satisfaction was rated as good or better by 304/394 responding patients (77%) at week 54 and in 1393/2065 patients (67%) by physicians overall. - Conclusions - In routine clinical practice, effectiveness and safety of first-line bevacizumab-containing therapy for LR/MBC were consistent with experience from phase III trials. Patient and physician treatment satisfaction showed high concordance. | ||
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a Metastatic breast cancer | |
| 650 | 4 | |a Non-interventional study | |
| 700 | 1 | |a Ruhnke, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffmann, Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grafe, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tomé, Oliver |d 1967- |e VerfasserIn |0 (DE-588)120682915 |0 (DE-627)08082711X |0 (DE-576)179262394 |4 aut | |
| 700 | 1 | |a Fett, Werner |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bruch, Harald-Robert |d 1964- |e VerfasserIn |0 (DE-588)1059512556 |0 (DE-627)79860705X |0 (DE-576)415664497 |4 aut | |
| 700 | 1 | |a Sommer-Joos, Ann-Katrin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The breast |d Amsterdam [u.a.] : Elsevier, 1992 |g 60(2021), Seite 70-77 |h Online-Ressource |w (DE-627)320475042 |w (DE-600)2009043-2 |w (DE-576)103868151 |x 1532-3080 |7 nnas |a First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer real-world experience from >2000 patients treated in the multicentre AVANTI study |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g pages:70-77 |g extent:8 |a First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer real-world experience from >2000 patients treated in the multicentre AVANTI study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.breast.2021.08.014 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0960977621004446 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221206 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 9 |y j | ||
| 999 | |a KXP-PPN1824563922 |e 4225585115 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Volkmar Müller, Markus Ruhnke, Oliver Hoffmann, Andrea Grafe, Oliver Tomé, Werner Fett, Harald-Robert Bruch, Ann-Katrin Sommer-Joos, Andreas Schneeweiss"]},"note":["Online veröffenticht am 27. August 2021, Artikelversion vom 3. September 2021","Gesehen am 06.12.2022"],"person":[{"role":"aut","family":"Müller","given":"Volkmar","display":"Müller, Volkmar"},{"given":"Markus","display":"Ruhnke, Markus","role":"aut","family":"Ruhnke"},{"display":"Hoffmann, Oliver","given":"Oliver","role":"aut","family":"Hoffmann"},{"display":"Grafe, Andrea","given":"Andrea","family":"Grafe","role":"aut"},{"display":"Tomé, Oliver","given":"Oliver","role":"aut","family":"Tomé"},{"role":"aut","family":"Fett","given":"Werner","display":"Fett, Werner"},{"display":"Bruch, Harald-Robert","given":"Harald-Robert","role":"aut","family":"Bruch"},{"given":"Ann-Katrin","display":"Sommer-Joos, Ann-Katrin","family":"Sommer-Joos","role":"aut"},{"display":"Schneeweiss, Andreas","given":"Andreas","role":"aut","family":"Schneeweiss"}],"recId":"1824563922","physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1016/j.breast.2021.08.014"],"eki":["1824563922"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer","subtitle":"real-world experience from >2000 patients treated in the multicentre AVANTI study","title_sort":"First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer"}],"origin":[{"dateIssuedDisp":"December 2021","dateIssuedKey":"2021"}],"relHost":[{"id":{"eki":["320475042"],"issn":["1532-3080"],"zdb":["2009043-2"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"breast","title":"The breast"}],"origin":[{"dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; Burlington, Mass.","publisher":"Elsevier ; Harcourt","dateIssuedDisp":"1992-"}],"recId":"320475042","disp":"First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer real-world experience from >2000 patients treated in the multicentre AVANTI studyThe breast","type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"60(2021), Seite 70-77","pages":"70-77","extent":"8","volume":"60","year":"2021"},"language":["eng"],"note":["Gesehen am 27.04.2020","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1992 -"]}]} | ||
| SRT | |a MUELLERVOLFIRSTLINEB2021 | ||